Growth Hormone (gh) Or Derivative Patents (Class 514/11.3)
  • Patent number: 10383919
    Abstract: The present invention features compositions and methods for delivery of growth hormone. We describe compositions comprising fragments of growth hormone-binding protein and, optionally, growth hormone. The compositions can be administered to a patient having a growth disorder or other disorder responsive to growth hormone.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: August 20, 2019
    Assignee: The University of the Sciences
    Inventors: Pardeep Gupta, Snehal Atwe
  • Patent number: 10155026
    Abstract: Disclosed are methods of treating pain in a mammal, which may include the step of administering human growth hormone to a mammal in need thereof. The pain treated by the disclosed methods may be of a type caused by inflammation induced mechanical and/or thermal hypersensitivity, and may include, for example, a pain type resulting from one or more conditions selected from peripheral injury pain, post-operative pain, cutaneous inflammation, cutaneous incision, muscle incision, or chronic pain. Disease states in which the disclosed methods may be used include fibromyalgia, sickle cell anemia, epidermolysis bullosa, erythromelalgia, complex regional pain syndrome, or generalized muscle pain.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 18, 2018
    Assignee: Children's Hospital Medical Center
    Inventors: Michael P. Jankowski, Xiaohua Liu, John Barns Rose
  • Patent number: 10064951
    Abstract: The present invention relates to a liquid formulation of highly concentrated long-acting human growth hormone conjugate, comprising a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent, and a method for preparing the same.
    Type: Grant
    Filed: March 23, 2013
    Date of Patent: September 4, 2018
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
  • Patent number: 10012649
    Abstract: The object of the present invention is to provide an early mastitis detection method that can detect mastitis easily and quickly when compared to the prior methods and also a biomarker to be used with the method. The object can be solved by a method of examining a mammary gland disease by using the level of cyclophilin A in a mammary gland or in milk as indicator. More specifically, the object can be a method of examining a mammary gland disease comprising steps (1) and (2) listed below; (1) a step of detecting cyclophilin A in the milk collected from an udder or an udder quarter of a subject and thereby determining the cyclophilin A level in the milk; and (2) a step of determining the onset of a mammary gland disease or the possibility of onset of a mammary gland disease in the udder or the udder quarter of the subject on the basis of the cyclophilin A level in the milk.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: July 3, 2018
    Assignee: TOHOKU UNIVERSITY
    Inventors: Hisashi Aso, Haruki Kitazawa, Koichi Watanabe, Shuichi Owada, Hitoshi Watanabe, Yuya Nagasawa, Shunsuke Someya, Yoriko Horikoshi, Nanami Itaya
  • Patent number: 9821033
    Abstract: The present specification provides, amongst other things, a method of treating scoliosis comprising delivering a therapeutically acceptable amount of a growth modulator to an epiphyseal growth plate to correct or compensate for disproportionate growth.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: November 21, 2017
    Assignee: KIERAN MURPHY LLC
    Inventor: Kieran Murphy
  • Patent number: 9309316
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 12, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Manisha D. Dali, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • Publication number: 20150147399
    Abstract: The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide.
    Type: Application
    Filed: December 9, 2014
    Publication date: May 28, 2015
    Inventors: Alexander Vol, Orna Gribova
  • Publication number: 20150147341
    Abstract: There is disclosed is a method of treating a pulmonary disease using a pyrimidinecarboxamide compound, and a pharmaceutical composition suitable for inhalation comprising the pyrimidinecarboxamide compound.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Publication number: 20150141328
    Abstract: Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a PLD-inducing compound, such as the cationic amphiphilic drugs (e.g. azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, IGF-1 or an IGF-1 analogue (e.g. insulin), GH, and mixtures thereof. The pharmaceutical compositions are effective to treat a variety of aliments to the eye including meibomian gland dysfunction, evaporative dry eye disease, lipid abnormalities in meibum or the tear film, and autoimmune diseases such as Sjögren's syndrome.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventors: David A. Sullivan, Juan Ding, Yang Liu, Wendy Kam
  • Publication number: 20150133383
    Abstract: The present invention concerns methods and tools for determining a specific treatment of a prolactin associated disorder. The treatment is selected based on the expression pattern of growth hormonereceptor (GHR), prolactin receptor (PrlR) and the suppressors SOCS2 and TCS2.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 14, 2015
    Inventor: Gunnar Norstedt
  • Publication number: 20150104484
    Abstract: The present disclosure is directed to articles comprising a polyelectrolyte complex which stores mechanical strain and methods of forming articles comprising a polyelectrolyte complex which stores mechanical strain.
    Type: Application
    Filed: September 22, 2014
    Publication date: April 16, 2015
    Inventors: Joseph B. Schlenoff, Qifeng Wang
  • Publication number: 20150104469
    Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 16, 2015
    Applicant: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
  • Publication number: 20150086607
    Abstract: A synthetic construct suitable for implantation into a biological organism that includes at least one polymer scaffold; wherein the at least one polymer scaffold includes at least one layer of polymer fibers that have been deposited by electrospinning; wherein the orientation of the fibers in the at least one polymer scaffold relative to one another is generally parallel, random, or both; and wherein the at least one polymer scaffold has been adapted to function as at least one of a substantially two-dimensional implantable structure and a substantially three-dimensional implantable tubular structure.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 26, 2015
    Inventors: Jed K. JOHNSON, Ross KAYUHA
  • Publication number: 20150080306
    Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 19, 2015
    Applicant: Duke University
    Inventor: Ashutosh Chilkoti
  • Publication number: 20150072934
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 12, 2015
    Applicants: Ono Pharmaceutical Co., Ltd., Helsinn Healthcare SA
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Marcia Philipson, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Patent number: 8969298
    Abstract: An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: March 3, 2015
    Assignees: Daiichi Sankyo Co., Ltd.
    Inventors: Masaru Matsumoto, Masako Matsumoto, Takeshi Hanada, Naomi Wakabayashi
  • Patent number: 8946155
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 3, 2015
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Patent number: 8945551
    Abstract: The invention relates to biopolymer-gel based depot systems for prolonged and/or controlled release delivery of biologically active agents, methods for the manufacture of the biopolymer based gel-depots which include a biologically active agent, and uses of such biopolymer gel-depots in therapy. The biopolymer-gel based depot systems comprise a biocompatible polyaminosaccharide and/or protein; a biocompatible phosphate and/or sulphonamide compound; a biologically active agent; an aqueous insoluble alkaline earth metal phosphate; and a biocompatible glycan and/or proteoglycan.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: February 3, 2015
    Assignee: Polymers CRC Ltd.
    Inventors: David Edward Mainwaring, Mohammad Al Kobaisi, Brendon Yew Loong Chua, David Charles Jackson
  • Publication number: 20140371136
    Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.
    Type: Application
    Filed: January 10, 2014
    Publication date: December 18, 2014
    Applicant: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
  • Publication number: 20140357558
    Abstract: Disclosed herein are compounds, compositions and methods for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: June 25, 2012
    Publication date: December 4, 2014
    Applicants: COLD SPRING HARBOR LABORATORY, ISIS PHARMACEUTICALS, INC.
    Inventors: Yimin Hua, Adrian R. Krainer, Frank Rigo, C. Frank Bennett
  • Publication number: 20140336117
    Abstract: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.
    Type: Application
    Filed: March 14, 2012
    Publication date: November 13, 2014
    Applicant: ASTERION LIMITED
    Inventors: Peter Artymiuk, Ian Wilkinson, Richard Ross
  • Publication number: 20140329750
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
  • Publication number: 20140315807
    Abstract: The invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolving. In particular, the inventive methods may be useful for treating or preventing conditions associated with bone degradation, deterioration or degeneration such as periodontal disease, osteoarthritis, and metastatic bone disease and osteolytic bone disease. Pharmaceutical compositions and kits comprising at least one resolving are also provided that can be used to performed the inventive methods.
    Type: Application
    Filed: December 19, 2013
    Publication date: October 23, 2014
    Applicant: The Forsyth Institute
    Inventor: Thomas E. Van Dyke
  • Publication number: 20140315795
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.
    Type: Application
    Filed: October 25, 2013
    Publication date: October 23, 2014
    Inventors: Maria del Carmen CARMONA OROZCO, Andrés Montefeltro, Gabriel Alvarado Urbina, Analía Bortolozzi Biassoni, Raquel Revilla-Sanchez
  • Publication number: 20140301974
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Application
    Filed: January 30, 2014
    Publication date: October 9, 2014
    Applicant: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Publication number: 20140287997
    Abstract: The invention relates to methods for treating stress sensitive condition, particularly depression. For instance a subject having or at risk of having a stress-sensitive condition such as depression may be treated with a growth hormone (GH) or an agonist thereof in an effective amount to treat depression.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: Massachusetts Institute of Technology
    Inventor: Ki Ann Goosens
  • Patent number: 8841249
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: September 23, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Henrik Sune Andersen, Jens Buchardt, Leif Norskov-Lauritsen
  • Patent number: 8833306
    Abstract: The present invention is related to the use of variants of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) to stimulate the growth and to improve the immunological system of aquatic organisms. The variants of the peptide were provided by immersion, injection or as a food additive.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: September 16, 2014
    Assignee: Centro de Ingenieria Genetica Y Biotecnologia
    Inventors: Juana Maria Lugo González, Mario Pablo Estrada Garcia, Alina Rodriguez Mallon, Yamila Carpio González, Antonio Morales Rojas, Osmany Rodrigo González De Sosa, Reynold Morales Fernández, Fidel Francisco Herrera Miyares
  • Publication number: 20140220046
    Abstract: Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
    Type: Application
    Filed: January 15, 2014
    Publication date: August 7, 2014
    Applicant: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
  • Patent number: 8778880
    Abstract: Modified human growth hormone polypeptides and uses thereof are provided.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: July 15, 2014
    Assignee: Ambrx, Inc.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
  • Publication number: 20140179598
    Abstract: Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic reagents, and methods of making and use thereof.
    Type: Application
    Filed: September 18, 2013
    Publication date: June 26, 2014
    Applicant: The Regents of the University of California
    Inventors: Murray Goodman, Sandra Blaj Moore
  • Publication number: 20140162953
    Abstract: A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 12, 2014
    Applicant: MEDIGENEBIO CORPORATION
    Inventors: Sy LEE, Sung-lck PARK
  • Publication number: 20140162944
    Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
    Type: Application
    Filed: May 25, 2012
    Publication date: June 12, 2014
    Applicant: CAMURUS AB
    Inventors: Fredrik Tiberg, Catalin Nistor, Markus Johnsson
  • Patent number: 8729019
    Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: May 20, 2014
    Assignee: Mannkind Corporation
    Inventors: Keith A. Oberg, Joseph Sulner
  • Publication number: 20140135260
    Abstract: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Zheng Xin DONG, Yeelana SHEN
  • Publication number: 20140086972
    Abstract: A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 27, 2014
    Applicant: Delpor, Inc.
    Inventors: Francis J. Martin, Anthony A. Bolarski
  • Publication number: 20140088012
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Application
    Filed: May 10, 2012
    Publication date: March 27, 2014
    Applicant: ARES TRADING S.A.
    Inventors: Pascal Croteau, Benoit Destenaves, Clement Olivier, John Raelson
  • Patent number: 8680050
    Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in administration to animals.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: March 25, 2014
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-Wei Wang, Nathan Geething, Jeffrey L. Cleland
  • Publication number: 20140079754
    Abstract: A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 20, 2014
    Applicant: Delpor, Inc.
    Inventors: Francis J. Martin, Anthony A. Boiarski
  • Publication number: 20140073570
    Abstract: Disclosed are compositions and methods for treating a patient with a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins, wherein the pharmaceutical composition is in the form of an emulsified nasal spray comprising: a macrocyclic permeation enhancer, a liquid carrier comprising water, and a therapeutically effective amount of a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins; wherein the macrocyclic permeation enhancer is a Hsieh enhancer emulsified in the liquid carrier.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 13, 2014
    Inventors: Robert J. GYURIK, Carl REPPUCCI
  • Publication number: 20140072531
    Abstract: A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol aqueous solution, the polymer microparticles prepared thereby, and use for drug delivery of the polymer microparticles.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 13, 2014
    Applicant: SK CHEMICALS CO., LTD.
    Inventors: Hong Kee KIM, Kyu Ho Lee, Joon-Gyo OH, Bong-Yong Lee
  • Publication number: 20140023668
    Abstract: In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula: (I) and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of ring A, ring B, ring C, R2, R3, R4, m, n, p, and -L1- is as defined herein. The novel compounds of the invention may be useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: April 4, 2012
    Publication date: January 23, 2014
    Inventors: Jared N. Cumming, Eric J. Gilbert, Andrew W. Stamford
  • Publication number: 20140004175
    Abstract: Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.
    Type: Application
    Filed: June 18, 2013
    Publication date: January 2, 2014
    Applicant: Compugen Ltd.
    Inventors: Yossef KLIGER, Itamar Borukhov, Ofer Levy, Zohar Tiran, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Amir Toporik
  • Publication number: 20130337076
    Abstract: The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof.
    Type: Application
    Filed: March 5, 2012
    Publication date: December 19, 2013
    Applicants: UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE, UNIVERSITE DE ROUEN
    Inventors: Ebba Brakenhielm, Sébastien Banquet, Florence Edwards-Levy, Christian Thuillez
  • Publication number: 20130331319
    Abstract: A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.
    Type: Application
    Filed: July 22, 2013
    Publication date: December 12, 2013
    Inventors: Nicholas V. Perricone, Chim Potini
  • Patent number: 8586532
    Abstract: The present invention relates generally to a novel method of introducing property modifying groups to a protein. In particular, the present invention relates to the derivatization of lysine residues, as well as new conjugates of growth hormones with improved pharmacological properties, and methods for their preparation and use in therapy.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: November 19, 2013
    Assignee: Novo Nordisk Healthcare A/G
    Inventors: Jens Buchardt, Nils Langeland Johansen
  • Publication number: 20130303444
    Abstract: The present invention relates to crystalline polymorphic forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, pharmaceutical compositions containing the same, methods of preparing the same, and methods for facilitating the delivery of active agents with the same.
    Type: Application
    Filed: April 5, 2013
    Publication date: November 14, 2013
    Applicant: Emisphere Technologies, Inc.
    Inventors: Nikhil DHOOT, Steven DINH, Shingai MAJURU, William Elliott BAY, JoAnne P. CORVINO, Doris C. O'TOOLE
  • Publication number: 20130259910
    Abstract: A method for use of a double-structured tissue implant or a secondary scaffold stand alone implant for treatment of tissue defects. The double-structured tissue implant comprising a primary scaffold and a secondary scaffold consisting of a soluble collagen solution in combination with a non-ionic surfactant generated and positioned within the primary scaffold. A method of use of a stand alone secondary scaffold implant or unit for treatment of tissue defects.
    Type: Application
    Filed: May 20, 2013
    Publication date: October 3, 2013
    Applicant: HISTOGENICS CORPORATION
    Inventors: Sonya Shortkroff, Laurence J. B. Tarrant, Eric J. Roos, Robert Lane Smith, Hans P. I. Claesson
  • Publication number: 20130230598
    Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.
    Type: Application
    Filed: February 20, 2013
    Publication date: September 5, 2013
    Applicant: LG LIFE SCIENCES, LTD., INC.
    Inventors: Myung-Jin KIM, Sun-Jin KIM, Oh-Ryong KWON